Table 2.
Observed 5-year survival and adjusted hazard ratios (HR) with 95% confidence intervals (CI) for gastric non-cardia adenocarcinoma and gastric cardia adenocarcinoma 1990–2017
| Covariate | Category | Gastric non-cardia adenocarcinoma | Gastric cardia adenocarcinoma | ||||
|---|---|---|---|---|---|---|---|
| Number of patients (%) | Observed 5-year survival (95% CI) | HR (95% CI)a | Number of patients | Observed 5-year survival (95% CI) | HR (95% CI)a | ||
| All patients | |||||||
| Calendar period | 1990–1994 | 5052 (29) | 15 (14–16) | 1.11 (1.05–1.17) | 960 (20) | 10 (8–12) | 1.31 (1.18–1.45) |
| 1995–1999 | 4095 (23) | 16 (15–17) | 1.08 (1.02–1.15) | 976 (21) | 9 (7–11) | 1.33 (1.20–1.47) | |
| 2000–2004 | 3472 (20) | 14 (13–15) | 1.09 (1.03–1.16) | 956 (20) | 10 (8–12) | 1.25 (1.13–1.38) | |
| 2005–2009 | 2830 (16) | 14 (13–15) | 1.07 (1.01–1.14) | 986 (21) | 14 (12–16) | 1.07 (0.97–1.19) | |
| 2010–2013 | 2042 (12) | 16 (15–18) | 1 (reference) | 820 (17) | 16 (13–18) | 1 (reference) | |
| Age (years) | < 60 | 2438 (14) | 23 (21–25) | 1 (reference) | 963 (26) | 18 (16–20) | 1 (reference) |
| 60–69 | 3417 (20 | 20 (18–21) | 1.08 (1.02–1.15) | 1238 (32) | 15 (13–17) | 1.10 (1.01–1.21) | |
| 70–79 | 6168 (35) | 16 (15–17) | 1.18 (1.12–1.24) | 1505 (21) | 10 (9–12) | 1.31 (1.19–1.43) | |
| ≥ 80 | 5468 (31) | 7 (7–8) | 1.65 (1.56–1.74) | 992 (21) | 3 (2–4) | 1.99 (1.80–2.20) | |
| Sex | Male | 10,132 (58) | 15 (14–16) | 1 (reference) | 3593 (76) | 12 (11–13) | 1 (reference) |
| Female | 7359 (42) | 15 (15–16) | 0.99 (0.56–1.02) | 1105 (24) | 11 (9–13) | 1.04 (0.97–1.12) | |
| Comorbidity score | 0 | 9160 (52) | 19 (18–20) | 1 (reference) | 2653 (56) | 14 (13–15) | 1 (reference) |
| 1 | 5947 (34) | 12 (11–13) | 1.29 (1.24–1.33) | 1405 (30) | 10 (8–11) | 1.0 (1.12–1.29) | |
| ≥ 2 | 2384 (14) | 9 (7–10) | 1.38 (1.31–1.45) | 640 (14) | 5 (3–6) | 1.38 (1.26–1.51) | |
| Surgery | |||||||
| Calendar period | 1990–1994 | 2498 (32) | 27 (25–29) | 1.46 (1.32–1.62) | 461 (25) | 17 (14–21) | 2.08 (1.73–2.51) |
| 1995–1999 | 1872 (24) | 30 (28–32) | 1.34 (1.20–1.48) | 384 (21) | 21 (17–25) | 1.81 (1.50–2–20) | |
| 2000–2004 | 1544 (20) | 29 (27–31) | 1.37 (1.23–1.52) | 378 (20) | 21 (17–25) | 1.72 (1.42–2.09) | |
| 2005–2009 | 1128 (14) | 32 (29–35) | 1.20 (1.07–1.34) | 363 (20) | 33 (28–37) | 1.26 (1.03–1.54) | |
| 2010–2013 | 786 (10) | 39 (36–43) | 1 (reference) | 269 (15) | 39 (33–45) | 1 (reference) | |
| Age (years) | < 60 | 1296 (17) | 39 (37–42) | 1 (reference) | 516 (28) | 30 (26–34) | 1 (reference) |
| 60–69 | 1763 (23) | 35 (33–37) | 1.10 (1.01–1.21) | 617 (33) | 26 (22–29) | 1.14 (0.99–1.31) | |
| 70–79 | 3109 (40) | 29 (27–31) | 1.25 (1.15–1.35) | 601 (32) | 22 (19–25) | 1.24 (1.07–1.42) | |
| ≥ 80 | 1660 (21) | 20 (18–22) | 1.61 (1.47–1.76) | 121 (7) | 15 (9–22) | 1.60 (1.28–1.99) | |
| Sex | Male | 4597 (59) | 29 (28–31) | 1 (reference) | 1491 (80) | 24 (22–26) | 1 (reference) |
| Female | 3231 (41) | 31 (29–33) | 0.96 (0.91–1.02) | 364 (20) | 29 (25–34) | 0.86 (0.75–0.99) | |
| Comorbidity score | 0 | 4578 (58) | 35 (33–36) | 1 (reference) | 1211 (65) | 27 (25–30) | 1 (reference) |
| 1 | 2445 (31) | 25 (23–26) | 1.28 (1.20–1.35) | 480 (26) | 24 (20–28) | 1.17 (1.03–1.32) | |
| ≥2 | 805 (10) | 21 (18–24) | 1.41 (1.29–1.54) | 164 (9) | 11 (6–16) | 1.60 (1.34–1.91) | |
| No surgery | |||||||
| Calendar period | 1990–1994 | 2554 (26) | 3 (2–3) | 1.22 (1.14–1.30) | 499 (18) | 2 (0.9–4) | 1.41 (1.24–1.59) |
| 1995–1999 | 2223 (23) | 4 (3–5) | 1.12 (1.04–1.20) | 592 (21) | 1 (0.2–2) | 1.41 (1.25–1.59) | |
| 2000–2004 | 1928 (20) | 2 (2–3) | 1.10 (1.02–1.18) | 578 (20) | 2 (0.9–3) | 1.26 (1.12–1.42) | |
| 2005–2009 | 1702 (18) | 2 (2–3) | 1.07 (0.99–1.15) | 623 (22) | 3 (2–5) | 1.09 (0.97–1.23) | |
| 2010–2013 | 1256 (13) | 2 (1–3) | 1 (reference) | 551 (19) | 4 (3–6) | 1 (reference) | |
| Age (years) | < 60 | 1142 (12) | 4 (3–5) | 1 (reference) | 447 (16) | 4 (2–6) | 1 (reference) |
| 60–69 | 1654 (17) | 4 (3–4) | 1.07 (0.99–1.15) | 621 (22) | 3 (2–5) | 1.02 (0.90–1.16) | |
| 70–79 | 3059 (32) | 3 (2–4) | 1.15 (1.07–1.23) | 904 (32) | 3 (2–4) | 1.10 (0.97–1.23) | |
| ≥ 80 | 3808 (39) | 1 (1–2) | 1.17 (1.09–1.26) | 871 (31) | 1 (0.5–2) | 1.18 (0.98–1.17) | |
| Sex | Male | 5535 (57) | 3 (2–3) | 1 (reference) | 2102 (74) | 3 (1–3) | 1 (reference) |
| Female | 4128 (43) | 2 (2–3) | 0.98 (0.94–1.02) | 741 (26) | 2 (1–3) | 1.07 (0.98–1.17) | |
| Comorbidity score | 0 | 4582 (47) | 4 (3–5) | 1 (reference) | 1442 (51) | 3 (2–4) | 1 (reference) |
| 1 | 3502 (36) | 3 (1–4) | 1.18 (1.13–1.23) | 925 (33) | 2 (2–3) | 1.10 (1.01–1.20) | |
| ≥ 2 | 1579 (16) | 2 (1–3) | 1.11 (1.05) | 476 (17) | 2 (1–4) | 1.08 (0.97–1.20) | |
aAdjusted for calendar period, age, sex, and comorbidity